RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Clinical trials for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 participants will receive o…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:14 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial underway
Disease control OngoingThis study looks at three different drug combinations for women with ovarian, fallopian tube, or primary peritoneal cancer that has returned and is no longer responding to platinum-based chemotherapy. The trial compares a standard chemotherapy drug (pegylated liposomal doxorubici…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
New drug combo shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial tests a combination of three drugs—ZEN003694, nivolumab, and ipilimumab—in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink or stabilize the canc…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC